Exponent, Inc. (NASDAQ:EXPO) Shares Sold by Metropolitan Life Insurance Co NY

Metropolitan Life Insurance Co NY lessened its stake in shares of Exponent, Inc. (NASDAQ:EXPO) by 2.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,203 shares of the business services provider’s stock after selling 336 shares during the period. Metropolitan Life Insurance Co NY’s holdings in Exponent were worth $935,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Bronfman E.L. Rothschild L.P. lifted its position in Exponent by 580.9% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 926 shares of the business services provider’s stock valued at $47,000 after purchasing an additional 790 shares during the last quarter. Bremer Trust National Association bought a new stake in shares of Exponent in the 4th quarter worth approximately $55,000. Bremer Bank National Association bought a new stake in shares of Exponent in the 1st quarter worth approximately $55,000. Quadrant Capital Group LLC lifted its holdings in shares of Exponent by 961.2% in the 1st quarter. Quadrant Capital Group LLC now owns 1,040 shares of the business services provider’s stock worth $57,000 after acquiring an additional 942 shares during the last quarter. Finally, Ellis Investment Partners LLC bought a new stake in shares of Exponent in the 1st quarter worth approximately $90,000. Institutional investors and hedge funds own 88.68% of the company’s stock.

In other Exponent news, Director Carol Lindstrom sold 1,800 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $56.92, for a total transaction of $102,456.00. Following the completion of the sale, the director now directly owns 3,212 shares of the company’s stock, valued at approximately $182,827.04. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 2.30% of the company’s stock.

Exponent stock traded up $0.73 during mid-day trading on Thursday, reaching $61.54. The stock had a trading volume of 166,284 shares, compared to its average volume of 197,545. The firm has a market cap of $3.16 billion, a P/E ratio of 49.23 and a beta of 0.44. The company’s 50-day moving average price is $58.35. Exponent, Inc. has a one year low of $44.44 and a one year high of $61.71. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.22 and a quick ratio of 4.22.

Exponent (NASDAQ:EXPO) last posted its earnings results on Thursday, April 18th. The business services provider reported $0.42 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.35 by $0.07. Exponent had a net margin of 19.53% and a return on equity of 23.10%. The business had revenue of $93.40 million for the quarter, compared to analysts’ expectations of $93.52 million. During the same quarter in the prior year, the business earned $0.75 EPS. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. On average, analysts forecast that Exponent, Inc. will post 1.42 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, June 21st. Investors of record on Friday, June 7th were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 1.04%. The ex-dividend date of this dividend was Thursday, June 6th. Exponent’s dividend payout ratio is 51.20%.

A number of research firms recently commented on EXPO. William Blair reiterated a “market perform” rating on shares of W W Grainger in a report on Monday, April 22nd. Cantor Fitzgerald reissued a “buy” rating on shares of Tivity Health in a research report on Monday, April 22nd. BidaskClub downgraded shares of Ames National from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, Zacks Investment Research raised shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Tuesday. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $62.33.

About Exponent

Exponent, Inc, together with its subsidiaries, operates as a science and engineering consulting company worldwide. Its services include analysis of product development, product recall, regulatory compliance, and the discovery of potential problems related to products, people, property, and impending litigation.

Featured Story: The Structure of a Futures Contract

Institutional Ownership by Quarter for Exponent (NASDAQ:EXPO)

Receive News & Ratings for Exponent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exponent and related companies with MarketBeat.com's FREE daily email newsletter.